REM2 Inhibitors

Chemical inhibitors of REM2 target various aspects of its regulation and function through interference with the protein kinase C (PKC) pathway, which is critical for the activity of REM2. Phorbol 12-myristate 13-acetate (PMA) is a known activator of PKC and through sustained activation can lead to PKC downregulation, which in turn can inhibit REM2 by reducing PKC-mediated phosphorylation that is essential for REM2's activity. Similarly, Gö 6983, a broad-spectrum PKC inhibitor, can inhibit REM2 activity by halting the phosphorylation events necessary for its function. Chelerythrine chloride, another PKC inhibitor, can inhibit REM2 by preventing the phosphorylation necessary for its activation or stability. Bisindolylmaleimide I (BIM I) specifically inhibits PKC, thereby leading to the inhibition of REM2 by obstructing the phosphorylation cascade crucial for REM2's regulation and function.

Staurosporine, although a non-specific kinase inhibitor, can inhibit REM2 by blocking the kinase activity required for the activation or functionality of REM2. Sotrastaurin (AEB071), as a selective PKC inhibitor, inhibits REM2 by interfering with PKC-mediated signaling events that regulate REM2's activity. Ro-31-8220 and Ro-32-0432, both potent PKC inhibitors, can inhibit REM2 activity by disrupting PKC-mediated signaling pathways. Balanol obstructs the ATP binding site of PKC necessary for the regulation of REM2 activity, thereby inhibiting REM2. Ruboxistaurin (LY333531) and Enzastaurin (LY317615) are selective inhibitors of PKCβ, and by preventing PKCβ-mediated signaling pathways, they can inhibit the function of REM2. Lastly, C1-2, a diacylglycerol (DAG) analogue, can lead to the inhibition of REM2 by acting as a PKC agonist initially but ultimately results in the downregulation of PKC over time, reducing PKC-mediated phosphorylation events that are critical for the activity of REM2.